- Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancersJacqueline Lehmann-Che
INSERM CNRS University Paris 7, UMR 944 7212, Hopital Saint Louis, 1, Av Claude Vellefaux, 75 475 Paris Cedex 10, France
Oncologist 15:246-52. 2010..The latter allowed very high levels of pCR in triple-negative tumors. Thus, our data strongly suggest that cyclophosphamide dose intensification in ER(-) p53-mutated breast cancer patients could significantly improve their response...